DNLIDenali Therapeutics Inc.

$3B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$52M+128.8% YoY

Gross Profit

$52M100.0% margin

Operating Income

-$61M-117.0% margin

Net Income

-$59M-112.0% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+24.5%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$46M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$408M

Stockholders' Equity

$884M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$52M	$23M	+128.8%
Gross Profit	$52M	$23M	+128.8%
Operating Income	-$61M	-$62M	+0.6%
Net Income	-$59M	-$61M	+3.1%

DNLI Q2 2022 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena